Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.22 USD
Change Today +0.16 / 3.94%
Volume 184.3K
As of 4:00 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/1/14 - $13.19
52 Week Low
10/1/15 - $3.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. It has a collaboration agreement with Heat Biologics, Inc. to evaluate the combination of immunotherapy platforms. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Announces Positive Results from Phase II Trial of Immunopulse IL-12 in Merkel Cell Carcinoma

OncoSec Medical Incorporated announced results from a Phase II trial demonstrating that its investigational therapy, ImmunoPulse IL-12, promotes tumor-specific, systemic anti-tumor immune responses in patients with Merkel cell carcinoma (MCC). Shailender Bhatia, MD, Assistant Professor of Medicine, Division of Medical Oncology at the University of Washington School of Medicine and Principal Investigator of the trial, presented the findings in an oral presentation at the 2015 European Cancer Congress in Vienna, Austria. In this Phase II study, 79% of patients (11/14) showed an increase in IL-12 protein levels in tumor biopsy samples obtained approximately 22 days after treatment compared to baseline, indicating that ImmunoPulse IL-12 leads to successful DNA transfection and sustained protein expression within the tumor microenvironment. ImmunoPulse IL-12 was well-tolerated, with no treatment-related adverse events above Grade 2 and no treatment-related serious adverse events. The most common adverse event was Grade 1 transient pain associated with the treatment procedure. Analysis of individual lesions found that 30% of patients (3/10) who were evaluable for systemic anti-tumor immunity had regression of at least one distant, non-injected/non-electroporated lesion. In patients considered evaluable for objective response by modified RECIST criteria, 25% of patients (3/12) had an objective partial response (PR) and one patient had stable disease (SD) for a disease control rate (PR + SD) of 33%. In Cohort A (N=3), one patient had a pathologic complete response and continues to be recurrence-free at six months. Another patient has been recurrence-free for over three years. Immune correlative data suggest that ImmunoPulse IL-12 can increase tumor-infiltrating lymphocytes and may promote a tumor-specific CD8+ T-cell response.

OncoSec Medical Incorporated Appoints David P. Meininger as Senior Vice President of Business Development

OncoSec Medical Incorporated announced the appointment of David P. Meininger, PhD, MBA, to the newly created position of Senior Vice President of Business Development, effective September 14, 2015. In this role, Dr. Meininger will be responsible for developing new business and strategic partnerships as well as potential licensing opportunities. He will also manage all corporate development activities for the Company's therapeutic products. Most recently, Dr. Meininger served as Executive Director, Business Development and Licensing at Merck & Co. Inc., where he was the global lead for biologics technologies and was responsible for West Coast in-licensing opportunities in immuno-oncology and other therapy areas.

OncoSec Medical Incorporated Promotes Sheela Mohan-Peterson to Chief Legal and Compliance Officer

OncoSec Medical Incorporated promoted Sheela Mohan-Peterson, JD, MS, to Chief Legal and Compliance Officer, effective August 24, 2015. In this role, Ms. Mohan-Peterson will advise the company's officers and Board of Directors on all major legal matters and continue to lead the company's intellectual property portfolio and global legal strategy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $4.22 USD +0.16

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at